Journal
CYTOKINE & GROWTH FACTOR REVIEWS
Volume 20, Issue 5-6, Pages 409-418Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.cytogfr.2009.10.021
Keywords
High throughput screen; Bone morphogenetic protein; TGF-beta; Anemia; Hepcidin; Cardiomyocyte; Embryonic stem cell; Fibrodysplasia ossificans progressiva; Bone mineral density
Categories
Funding
- NIH [K08HL081535, K08HL079943]
- GSK Cardiovascular Research and Education Foundation
- Veterans Health Administration
- Center for Research in Fibrodysplasia Ossificans and Related Disorders
- Pulmonary Hypertension Association
- Massachusetts Technology Transfer Center
- Howard Hughes Medical Institute
- Harvard Stem Cell Institute
- NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL079943, K08HL081535] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Bone morphogenetic proteins (BMPs) provide critical signals for determining cell fate, specifying gastrulation, embryonic patterning, organogenesis, and the remodeling of diverse tissues. Recent work has suggested that in addition to coordinating pivotal events in development, BMPs may also regulate certain homeostatic physiological processes independently of effects on cell growth or differentiation. We recently described the identification of dorsomorphin, a small molecule inhibitor of BMP type I receptors which inhibits BMP signaling in preference to TGF-beta, Activin, and other ligands of the TGF-beta family. We describe a number of strategies using dorsomorphin and its derivatives as probes to assess the physiologic roles of BMP signaling. We also discuss several potential applications for small molecule BMP inhibitors, including stem cell manipulation, and the therapeutic modification of bone remodeling, heterotopic ossification, and iron homeostasis. (C) 2009 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available